Research, on innovation appointment in Milan with Novartis

Innovation, scientific and pharmaceutical research: these are the themes at the heart of ‘Breakthrough Science’, an event promoted today by Novartis in Milan, which precedes the Global initiative in Basel. The event, which sees the participation of journalists from all over Europe, is an opportunity for the Swiss giant to illustrate some innovative programs included in the development pipeline of the main therapeutic areas in which the company operates and the portfolio of molecules that represent new potential treatments for unmet medical needs. The meeting will be held this morning starting at 12.00 in the Lombard capital, at Havas Village Italia, in the presence of Pasquale Frega, Country President Novartis Italia and Ad Novartis Farma, Eva Runggdalier, Country Head of Trial Monitoring and Paolo Orsenigo, Medical Franchise Leader. Breakthrough Science objectives: to illustrate challenges and future scenarios of R&D in Italy and to take stock of developments and perspectives related to the Medical Affairs function.In the afternoon, however, it will be the turn of another event, in virtual mode, with interventions by John Tsai, Head of Global Drug Development and Chief Medical Officer of Novartis and Jay Bradner, President of the Novartis Institutes for Bio Medical Research (Nibr), in addition to the heads of Novartis R&D. The meeting will be an opportunity to take stock of the following therapeutic areas: kidney disease (“How to alleviate the burden of rare kidney diseases for young people”); lung cancer (“How to treat the KRAS protein mutation”); osteoarthritis (“Change of treatment paradigm with knee cartilage regrowth”); pancreatic cancer (“A new pathway that represents a milestone in the treatment of pancreatic cancer”); food allergy (“Reduce anxiety by blocking a receptor”); malaria (“Helping to create a malaria-free world”). So a look to the future with the debate on “Democratizing” cell and gene therapy.